A First-in-Human clinical study of CB5138 3
Latest Information Update: 21 May 2022
At a glance
- Drugs CB 5138 3 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; First in man
- 16 May 2022 According to a CohBar media release, the company expects to submit an Investigational New Drug Application for this program to the US Food and Drug Administration in the second half of 2023.
- 23 Mar 2021 New trial record
- 16 Mar 2021 According to a CohBar media release, the company expect to initiate this trial in 2022.